Optibrium raises investment to advance computer-aided drug discovery
Investment by Kester Capital will drive commercial growth and the development of new products to improve speed, efficiency, and productivity of the discovery process.
Avacta Group plc announces commercial partnership with Mologic
New partnership aims to accelerate CE marking of Avacta’s SARS-CoV-2 rapid antigen test and support COVID-19 testing in low and middle income countries.
FairJourney Biologics Group introduces Flow Eighteen38 for protein production and antibody characterization services
Porto, Portugal, 8th February 2021: FairJourney Biologics (FJB) and IONTAS, leaders in the discovery and optimization of antibodies, have today announced the launch of a new protein sciences division, Flow Eighteen38. The new business unit has been introduced to accelerate customer antibody research projects, by delivering reagents, purified proteins, and characterization data on antibody panels…
Avacta announces AffyXell $7.3 million Series A financing
Avacta’s next generation cell and gene therapy joint venture with Daewoong Pharmaceutical secures Series A venture funding.
Metrion Biosciences and Sosei Heptares to explore structure-based drug discovery (SBDD) approaches to ion channels through strategic technology collaboration
Cambridge, UK and Tokyo, Japan, 01 February 2021– Metrion Biosciences Limited, the specialist ion channel CRO and drug discovery company and Sosei Group Corporation (“the Company”; TSE: 4565), the international biopharmaceutical group, announce they will apply Sosei Heptares’ world-leading structure-based drug design (SBDD) expertise and platform to ion channels for the first time through a new…
Avacta announces collaboration agreement with Bruker
Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, announces that it has entered into a collaboration agreement with Bruker Corporation (Billerica, MA) to evaluate the Affimer-based, bead assisted mass spectrometry (BAMS™) SARS-CoV-2 assay, that the Group has developed with Adeptrix Inc.
Gyros Protein Technologies introduces Gyrolab Bioaffy 4000 CD to extend sensitivity of immunoassay CD range
Uppsala, Sweden...Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the introduction of Gyrolab® Bioaffy™ 4000 CD for immunoassay applications in biotherapeutic workflows. The new Gyrolab Bioaffy 4000, with a 4000 nL sample volume, is based on the proven design of Gyrolab Bioaffy 1000 CD,…
Dotmatics collaborates with HighRes Biosolutions to provide single software interface for lab digitalization
Bishop’s Stortford, UK, and Beverly, MA, 25 January 2021: Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced a partnership with HighRes Biosolutions (HighRes), a company that designs and builds innovative robotic systems and laboratory devices.
Optibrium enhances compound design strategies in major upgrade to StarDrop software
Optibrium™, a developer of software for drug discovery, has announced the release of the newest version of StarDrop™, a comprehensive software platform for small molecule design, optimisation and data analysis. The new release, StarDrop 7.0, further extends the software’s compound design strategies, provides enhanced workflows, and seamlessly connects with Optibrium’s Cerella™ platform,…